Patients receiving treatment guided by Personalized TumorGraft testing have seen shrinkage of their tumor for a significant period of time1.
Tested Tumor Types:
Champions TumorGrafts have been successfully tested in most tumor types including colorectal, ovarian, lung, breast, sarcoma, pancreatic, stomach, esophageal, mesothelioma and others..
Treatment Solutions Evaluated:
Champions TumorGrafts can predict the likely success of many therapies including single-agent and combination chemotherapy regimens, targeted biological drugs and antiangiogenics.
Dean, 63, Metastatic Pancreatic Cancer
Dean underwent extensive abdominal surgery to take out a cancer of the pancreas, but the cancer recurred 12 months after surgery. Dean was treated with the most common treatment (i.e., standard of care), the anticancer drug Gemcitabine, for four months until the cancer began to grow despite treatment.
Personalized TumorGraft Insights:
Based on Personalized TumorGraft evaluations, one of the treatments tested was the anticancer drug mitomycin C — which is rarely used to treat pancreatic cancer. This treatment showed a significant response in the Personalized TumorGraft™.
Example of Personalized TumorGraft results, showing how two of the treatments were more effective than the other tested. (This case was published in Molecular Cancer Therapeutics, Villarroel et al.)2
Targeted Treatment Results:
Based on Personalized TumorGraft findings, Dean received three cycles of Mitomycin C. His blood tumor marker (used to measure the tumor in the blood) was previously 98,000 and based on TumorGraft directed treatments was reduced to under 100. After 22 months of Dean was treated with two additional cycles of Mitomycin C and three cycles of Cisplatin.
Dean’s cancer remained in remission for over five years. The average survival of patients with metastatic pancreatic cancer is approximately six to eight months.
Individual outcomes may vary.